- I-SPY 2-Toward More Rapid Progress in Breast Cancer TreatmentCarey Lisa A*; Winer Eric PNew England Journal of Medicine, 2016, 375(1): 83-84.被引 2
- Comparison between her2, estrogen receptors and progesterone receptors in primary breast carcinomas and matched lymph node metastasesMohamed Mokhtar, Desouki; Ihab Shafek, Atta; Daynna J, Wolff; Sally E, SelfTurkish Journal of Pathology, 2016.
- Multi-omic subtyping and molecular determinants of neoadjuvant therapeutic regimen for locally advanced HER2-positive and triple-negative breast cancer: Implications of novel therapy.Ji, Fei; Chen, Xianzhe; Yang, Ci-Qiu; Zhang, Liulu; Yang, Mei; Li, Jieqing; Gao, Hong-Fei; Zhu, Teng; Cheng, Min-Yi; Chen, Yi-Tian; Peng, Hao; Zhu, Changbin; Li, Weiwei; Huang, Zhan; Wang, Jin; Wang, KunAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
期刊论文
HER2 Evaluation and Its Impact on Breast Cancer Treatment Decisions
4阅读
